This trial is evaluating whether Imsidolimab will improve 1 primary outcome in patients with Acne. Measurement will happen over the course of Change from baseline in facial inflammatory lesion count at week 12.
This trial requires 120 total participants across 3 different treatment groups
This trial involves 3 different treatments. Imsidolimab is the primary treatment being studied. Participants will be divided into 2 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
"Acne has various signs and symptoms, which can be identified by a simple questionnaire. Knowledge of symptoms also aids a diagnosis of other diseases that may coexist with, or be a contributing factor in, acne. We recommend this questionnaire for use when evaluating acne patients." - Anonymous Online Contributor
"Patients need to learn that acne is a chronic skin infection caused by abnormal production of sebum by sebaceous glands in certain areas of the skin. And unlike acne vulgaris, acne does not have immediate consequences in the form of visible bumps, scars, and discoloration. There is a need for increased awareness of the chronic nature of this skin condition, and for patients to be aware that once the infection has cleared, the skin returns to normal. One aspect of this disease is the necessity for self-analysis of one's own skin and hair condition, as many patients only discover the nature of their condition after a protracted course of antibiotics and oral retinoids." - Anonymous Online Contributor
"Acne is caused by a combination of the amount of oil and the quantity of bacteria and their virulence factors produced by the follicle. Skin color and body weight are important factors in the development of oily skin. Acne will resolve if the oily skin problem is addressed." - Anonymous Online Contributor
"There are often multiple treatments for acne, depending on its severity and the patient's willingness to try different treatments. Treatment may include prescription and OTC drugs, creams, keratoconjuctivs, and salons. Treatment is typically tailored to the treatment and severity of the patient's acne." - Anonymous Online Contributor
"There is currently no evidence that acne can be fixed or erased from a person's skin, but there is a growing belief that acne can be substantially reduced by medication." - Anonymous Online Contributor
"In a recent study, findings, acne affected 1% to 12% of people, according to the duration of the disease. About 7% of patients treated for acne had the disease for more than 5 years. The prevalence of acne decreased with age, and patients aged 75 years or older are less likely to have the disease, and the severity of it, but not of the disease." - Anonymous Online Contributor
"There was no increased prevalence of acne in both parents, siblings, or other relatives of affected cases. This suggests that acne does not run in families." - Anonymous Online Contributor
"The most common drug-related side effects of imsidolimab are rash, fever and upper respiratory tract infections. Most of the drugs commonly reported to cause rashes were not reported as side effects of imsidolimab. In addition, no serious hypersensitivity reactions were reported with regards to imsidolimab. Imsidolimab should be avoided in patients with a history of interstitial lung disease of pregnancy. Patients treated with imsidolomab should be closely monitored for potential side effects, including an increased risk for infections, with particular attention to opportunistic infections, due to drug-induced immunosuppression." - Anonymous Online Contributor
"Imsidolimab is an antibody for TNF-α and has been used in patients with Crohn's disease, psoriasis, psoriatic arthritis, ulcerative colitis, rheumatoid arthritis, and uveitis. For its ability to modulate the expression of inflammatory mediators and adhesion molecules, such as chemokines and integrins, it could be a useful drug for the treatment of rheumatic and other immune-mediated disorders." - Anonymous Online Contributor
"Recent findings obtained in subjects with more moderate to severe acne indicated that IM was more effective than placebo in inducing a faster clinical response (greater decrease of acne erythema), more rapid and extensive clearance and an earlier termination of the acne exacerbations." - Anonymous Online Contributor
"In a recent study, findings, imsidolimab did not demonstrate a significant reduction in QoL for patients with acne and should be considered as a second-line drug of treatment for this disease. These preliminary results should be considered in assessing the value of imsidolimab for this indication in the light of the recent literature." - Anonymous Online Contributor
"‘ImmD0’ shows activity with a safety profile similar to other CD20 inhibitors. Its mechanism of action is a unique CD20-independent signalling pathway, and the results confirm the potential of imsidolimib for treatment." - Anonymous Online Contributor